Hydrochlorothiazide (HCTZ) primarily lowers blood pressure by directly impacting the kidneys. It acts on the distal convoluted tubule, a section of the kidney responsible for reabsorbing sodium and water back into the bloodstream. HCTZ inhibits the sodium-chloride symporter (NCCT), a protein that actively transports sodium and chloride ions.
Reduced Sodium Reabsorption
By blocking the NCCT, HCTZ reduces the kidney’s reabsorption of sodium. This leads to increased sodium excretion in the urine. Because water follows sodium, this also increases water excretion, reducing blood volume.
Decreased Blood Volume and Pressure
Lower blood volume directly translates to lower blood pressure. The heart doesn’t need to work as hard to pump blood throughout the body, leading to a decrease in pressure against the artery walls. This is a key mechanism in HCTZ’s ability to lower blood pressure.
Impact on Potassium and Calcium
Important note: While HCTZ primarily affects sodium, its action also impacts other electrolytes. It can lead to some loss of potassium and, conversely, may slightly increase calcium levels in the blood. Monitoring these levels is often part of HCTZ therapy.
Synergistic Effects
Often, HCTZ is combined with other blood pressure medications. This combination therapy leverages synergistic effects, meaning the medications work better together than individually, resulting in more effective blood pressure control.
